Advanced search    

Search: authors:"A. Cooper"

8 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

and Pfizer; David A. Cooper has received honoraria and research grant support from Gilead Sciences, Merck Research Laboratories and Bristol–Myers Squibb; and Sean Emery has received research grant

Comparison of morbidity and mortality of very low birth weight infants in a Central Hospital in Johannesburg between 2006/2007 and 2013

Background Health protocols need to be guided by current data on survival and benefits of interventions within the local context. Periodic clinical audits are required to inform and update health care protocols. This study aimed to review morbidity and mortality in very low birth weight (VLBW) infants in 2013 compared with similar data from 2006/2007. Methods We performed a ...

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

Objective To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks. Design Open label, centrally randomised trial. Setting ...

Growth of a cohort of very low birth weight infants in Johannesburg, South Africa

Cheryl A Mackay 0 Daynia E Ballot 0 Peter A Cooper 0 0 Department of Paediatrics and Child Health, Charlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand , Johannesburg

The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa

Background There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART) following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with HIV/AIDS (PHA) reside. The aim of this study was to simulate the potential risks and benefits of treatment simplification in ...

Developmental outcome of very low birth weight infants in a developing country

Background Advances in neonatal care allow survival of extremely premature infants, who are at risk of handicap. Neurodevelopmental follow up of these infants is an essential part of ongoing evaluation of neonatal care. The neonatal care in resource limited developing countries is very different to that in first world settings. Follow up data from developing countries is essential; ...

Determinants of survival in very low birth weight neonates in a public sector hospital in Johannesburg

Background Audit of disease and mortality patterns provides essential information for health budgeting and planning, as well as a benchmark for comparison. Neonatal mortality accounts for about 1/3 of deaths < 5 years of age and very low birth weight (VLBW) mortality for approximately 1/3 of neonatal mortality. Intervention programs must be based on reliable statistics applicable ...

Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa

Sokal 4 Jeffrey D Klausner 3 Ross Appleton Nelson Sewankambo David A Cooper John Bongaarts Guy de Bruyn Alex D Wodak Joya Banerjee 0 Department of African-American Studies, Northeastern University